Nanoform, a nanoparticle medical technology company, has awarded AstraZeneca a global online STARMAP license. STARMAP is an AI-based digital rendition of CESS technology, facilitating in-silico experiments for selecting molecules to be nanoformed. This license enables AstraZeneca to screen molecules during the entire drug development process.
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Finnish nanoparticle medicine specialist Nanoform and German drugmaker Boehringer Ingelheim have agreed to collaborate on proof-of-concept studies related to Nanoform’s proprietary Controlled Expansion of Supercritical Solution (CESS) platform.
In 2019, the pharmaceutical industry invested $182 billion in drug development, but only 48 drugs were approved for use.
